Mizuho Maintains Buy on ResMed, Lowers Price Target to $160

ResMed Inc. +0.51% Pre

ResMed Inc.

RMD

174.61

174.61

+0.51%

0.00% Pre

Mizuho analyst Anthony Petrone maintains ResMed (NYSE: RMD) with a Buy and lowers the price target from $180 to $160.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via